CN-122005618-A - Application of bacillus amyloliquefaciens E35 in preparation of product for resisting garrupa iridovirus infection

Abstract

The application specifically discloses application of bacillus amyloliquefaciens E35 (Bacillus amyloliquefaciens) in preparation of an anti-grouper iridovirus infection product. Bacillus amyloliquefaciens E35 was deposited at the Cantonese microorganism strain collection at 20/12 of 2024 under accession number GDMCC 65657. The application of the bacillus amyloliquefaciens E35 in preparing the product for resisting the garrupa iridovirus infection has excellent control effect on the garrupa iridovirus, reduces the infection activity of the garrupa iridovirus on spleen cells, reduces the death rate of the garrupa iridovirus after the garrupa iridovirus infection, delays the onset time, and can reduce the drug resistance of fishes and the toxic and side effects on fish bodies caused by prevention and treatment.

Inventors

• GAO YANXIA
• WEI DONGDONG
• LI JIAXI
• ZHAO MINGMING
• Qin Xiangmou
• YU JIEYING
• Mou Rongli
• SONG CHAO
• XIE JINKUN
• LI PENGFEI
• YU QING
• LIU MINGZHU
• HAN SHUYU
• HUANG LIN
• LAI JUNXIANG
• YU ERMENG
• HUANG JING

Assignees

• 广西海洋科学院(广西红树林研究中心)
• 广西科学院
• 广西壮族自治区水产技术推广站

Dates

Publication Date

20260512

Application Date

20260115

Claims (8)

1. 1. The application of the bacillus amyloliquefaciens E35 in preparing the product for resisting the garrupa iridovirus infection is characterized in that the bacillus amyloliquefaciens E35 is preserved in the microorganism strain preservation center of Guangdong province at the 12 th month of 2024, and the preservation number is GDMCC 65657.
2. 2. The use of bacillus amyloliquefaciens E35 according to claim 1 for the preparation of a product against garrupa iridovirus infection, characterized in that: the product comprises at least one of bacillus amyloliquefaciens E35 viable bacteria or bacillus amyloliquefaciens E35 fermentation crude extract.
3. 3. The use of bacillus amyloliquefaciens E35 according to claim 1 for the preparation of a product against garrupa iridovirus infection, characterized in that: the grouper iridovirus is Epinephelus singapore iridovirus.
4. 4. The use of Bacillus amyloliquefaciens E35 in the preparation of a product for resisting garrupa iridovirus infection according to claim 1, wherein the product can inhibit the gene expression of the garrupa iridovirus envelope protein VP19 or/and main capsid protein MCP.
5. 5. The use of bacillus amyloliquefaciens E35 according to claim 1 for the preparation of a product against garrupa iridovirus infection, characterized in that: the product can improve fish survival rate.
6. 6. The use of bacillus amyloliquefaciens E35 according to any one of claims 1-5 for preparing a product for resisting garrupa iridovirus infection, wherein the product comprises any one of a microbial preparation and a fishing medicine.
7. 7. A microbial preparation for resisting garrupa iridovirus infection is characterized by comprising at least one of bacillus amyloliquefaciens E35 viable bacteria or bacillus amyloliquefaciens E35 fermented crude extract; the bacillus amyloliquefaciens E35 is preserved in the microorganism strain collection of Guangdong province at the 12 th month and 20 th year of 2024, and the preservation number is GDMCC 65657.
8. 8. A fishing medicine for resisting the infection of garrupa iridovirus is characterized by comprising at least one of bacillus amyloliquefaciens E35 viable bacteria or bacillus amyloliquefaciens E35 fermented crude extract; the bacillus amyloliquefaciens E35 is preserved in the microorganism strain collection of Guangdong province at the 12 th month and 20 th year of 2024, and the preservation number is GDMCC 65657.

Description

Application of bacillus amyloliquefaciens E35 in preparation of product for resisting garrupa iridovirus infection Technical Field The application relates to the field of aquatic antiviral microorganisms, in particular to application of bacillus amyloliquefaciens E35 in preparation of an anti-grouper iridovirus infection product. Background The groupers are high-quality sea water economic farmed fishes in China because the groupers are fresh and tender in meat quality and rich in various nutrient elements, and have high nutritive value and market requirements. According to the data of 2025 Chinese fishery statistics annual book, the annual output of groupers is in an increasing trend year by year. However, intensive cultivation causes the disease of groupers to frequently occur, wherein the viral disease has high transmission speed and high mortality rate. Among them, the hazard of the Epinephelus singapore iridovirus (Singapore grouper iridovirus, SGIV) is particularly prominent, and can cause symptoms such as splenomegaly and systemic hemorrhage. At present, no effective prevention and treatment measures are available for the garrupa iridovirus disease, so that economic loss is caused for the garrupa breeding industry, and sustainable development of the garrupa breeding industry is restricted. The existing prevention and treatment means mainly comprise drug therapies such as vaccines, antibiotics and the like. However, SGIV infection causes the body immune system to be blocked, and thus immunosuppression is caused, thereby causing secondary infection or mixed infection of bacteria such as vibrio harveyi, mermaid luminous bacillus and the like, resulting in poor cross protection effect between heterologous strains, so that the protection efficacy of the existing vaccine is limited. On the other hand, the traditional antibiotic chemotherapy has very little curative effect on iridovirus diseases and the like, and is easy to cause the formation or enhancement of bacterial drug resistance. Meanwhile, excessive antibiotics are applied to the water environment, so that the problems of medicine residue and the like are caused, water environment pollution and ecological system damage are caused, and medicines such as antibiotics are accumulated in aquatic products and are transmitted to human beings through food chains, so that the health of the human beings is threatened. Therefore, there is an urgent need to find alternative control strategies that can effectively control pathogens such as SGIV and retain growth promoting properties similar to antibiotics. Disclosure of Invention In view of the serious harmfulness and the current prevention and control situation of the grouper iridovirus in the grouper breeding industry, the application provides the application of the bacillus amyloliquefaciens E35 in preparing the grouper iridovirus infection resistant product. In a first aspect, the application provides an application of bacillus amyloliquefaciens E35 (Bacillus amyloliquefaciens) in preparing an anti-grouper iridovirus infection product, which adopts the following technical scheme: Application of bacillus amyloliquefaciens E35 in preparing anti-grouper iridovirus infection products, wherein the bacillus amyloliquefaciens E35 is deposited in the Guangdong province microorganism strain collection at the 12 th month 20 of 2024, and the deposit number is GDMCC 65657 and Latin name is Bacillus amyloliquefaciens. Bacillus amyloliquefaciens is a microorganism which can metabolize various antibacterial active substances and is beneficial to a host, and is known as a water probiotics, but under the traditional research paradigm, researchers usually cannot directly apply the bacillus amyloliquefaciens to the control of garrupa iridovirus. The research and application of probiotics are mainly focused on biological prevention and control of bacterial diseases and the probiotics function of the bacteria, so that the existing research at present is limited in the field of application research, and the probiotics are not applied to prevention and control of anti-garrupa iridovirus diseases based on the action mechanism of the probiotics. The grouper is infected with the grouper iridovirus and then the hematopoietic tissues are necrotized, and SGIV can be transmitted in the fish shoal in a horizontal infection mode, thereby negatively affecting the healthy development of fish culture. Through the research of related experiments, the bacillus amyloliquefaciens E35 can play an effective role in preventing and controlling SGIV. In addition, the bacillus amyloliquefaciens E35 has stronger capability of secreting amylase, protease, cellulase and other hydrolytic enzymes, has potential functions of promoting digestion and absorption of farmed animals, is beneficial to maintaining intestinal health barriers of fishes, inhibits other harmful microorganisms through competitive exclusion, indirectly improves the overall health state of